Scientists at Oxford University are accelerating the development of a new Ebola vaccine, with the potential for clinical trials to begin within two to three months. This urgent effort is in response to the current Ebola outbreak centered in the Democratic Republic of Congo, which has recorded 750 suspected cases and 177 deaths.

The specific strain of Ebola involved in the current emergency is known as Bundibugyo. This rare species of the virus has no proven vaccine and carries a significant fatality rate, killing approximately one-third of those infected. While the effectiveness of the new vaccine is not guaranteed and will require rigorous animal research and human trials, scientists are working with haste to prepare it in case the outbreak escalates.

The World Health Organization (WHO) recently upgraded the risk level from the current Ebola outbreak to "very high" within the Democratic Republic of Congo. The risk in the wider region is also now considered "high," although the international risk remains "low." This assessment follows the WHO's declaration of a public health emergency of international concern.

A separate experimental vaccine targeting Bundibugyo Ebola is also in development, but it is anticipated to take six to nine months before any doses are ready for testing. The UK-developed vaccine utilizes the same adaptable "ChAdOx1" technology that was employed during the Covid-19 pandemic. This platform allows for rapid modifications to target different infectious agents.

During the Covid-19 pandemic, the ChAdOx1 technology was adapted to carry genetic code from the SARS-CoV-2 virus. For the Ebola vaccine, it has been engineered to carry genetic material from the Bundibugyo Ebola virus. The vaccine uses a common chimpanzee-infecting cold virus, genetically modified for human safety, to deliver genetic instructions to cells. These instructions prompt cells to recognize and fight the actual Ebola virus without causing infection or symptoms.

Despite the rapid development, the WHO has indicated that there is currently no animal data available to support the effectiveness of this particular vaccine. A WHO spokesperson noted the possibility of doses being available for clinical trials in two to three months but emphasized the considerable uncertainty, contingent on the outcomes of animal trials.

This accelerated timeline reflects the critical need for effective countermeasures against a virus that has demonstrated a high mortality rate. The adaptability of the ChAdOx1 platform offers a promising avenue for a swift response to emerging infectious disease threats.

Further research and extensive clinical trials will be essential to determine the safety and efficacy of this new vaccine against the Bundibugyo Ebola virus. The coming months will be crucial in assessing whether this rapidly developed tool can become a vital part of the global response to the ongoing health emergency.